A048410 Stock Overview
Hyundai Bioscience Co., Ltd. operates as a biotechnology company.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Hyundai Bioscience Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩19,710.00 |
| 52 Week High | ₩41,200.00 |
| 52 Week Low | ₩17,600.00 |
| Beta | 1.17 |
| 1 Month Change | 2.18% |
| 3 Month Change | -17.36% |
| 1 Year Change | -1.70% |
| 3 Year Change | -58.37% |
| 5 Year Change | 55.81% |
| Change since IPO | 69.91% |
Recent News & Updates
Recent updates
The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About
Mar 14
Is Hyundai Bioscience (KOSDAQ:048410) Using Too Much Debt?
Feb 07
Imagine Holding Hyundai Bioscience (KOSDAQ:048410) Shares While The Price Zoomed 439% Higher
Jan 03The Trends At Hyundai Bioscience (KOSDAQ:048410) That You Should Know About
Nov 29Shareholder Returns
| A048410 | KR Personal Products | KR Market | |
|---|---|---|---|
| 7D | -1.7% | 6.2% | -4.3% |
| 1Y | -1.7% | -14.3% | -1.0% |
Return vs Industry: A048410 exceeded the KR Personal Products industry which returned -14.3% over the past year.
Return vs Market: A048410 matched the KR Market which returned -1% over the past year.
Price Volatility
| A048410 volatility | |
|---|---|
| A048410 Average Weekly Movement | 6.8% |
| Personal Products Industry Average Movement | 5.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A048410's share price has been volatile over the past 3 months.
Volatility Over Time: A048410's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Jong-Won Choi | www.hyundaibioscience.com |
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19.
Hyundai Bioscience Co., Ltd. Fundamentals Summary
| A048410 fundamental statistics | |
|---|---|
| Market cap | ₩784.82b |
| Earnings (TTM) | -₩14.50b |
| Revenue (TTM) | ₩9.48b |
82.8x
P/S Ratio-54.1x
P/E RatioIs A048410 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A048410 income statement (TTM) | |
|---|---|
| Revenue | ₩9.48b |
| Cost of Revenue | ₩4.49b |
| Gross Profit | ₩4.99b |
| Other Expenses | ₩19.49b |
| Earnings | -₩14.50b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -364.14 |
| Gross Margin | 52.65% |
| Net Profit Margin | -152.92% |
| Debt/Equity Ratio | 11.9% |
How did A048410 perform over the long term?
See historical performance and comparison